05:50 PM EDT, 06/24/2024 (MT Newswires) -- VTv Therapeutics ( VTVT ) said Monday the first patient was screened in a trial of cadisegliatin as an adjunct treatment of type 1 diabetes.

The registrational study will form the core of the regulatory submission for cadisegliatin, vTv said.

The study will evaluate the safety and efficacy of cadisegliatin over 12 months in type 1 diabetes patients, vTv said. The trial is expected to enroll 150 patients at up to 20 US sites.

The company plans to start a phase 2 study of the drug in Middle East countries as an adjunct therapy in patients with type 2 diabetes in H2.